12 gennaio 2026

TECregen, a Basel, Switzerland-based biotechnology company pioneering thymus regeneration, raised CHF 10 million in a seed financing round. The financing was led by the Boehringer Ingelheim Venture Fund (BIVF), with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, HighTech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. The investment will accelerate development of TECregen’s groundbreaking thymopoietic biologics, designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen overall immune resilience.

Walder Wyss advised TECregen on the financing round. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and Christoph Burckhardt (Senior Associate/M&A and Venture Capital) and further included Karina Tschon (Managing Associate, Corporate/M&A and Venture Capital) and Oerjan Wickart (Associate, Corporate/M&A and Venture Capital).